TOLREMO therapeutics
Clinical-stage biotechnology company developing small-molecule inhibitors that block transcriptional escape pathways driving non-genetic cancer drug resistance. The organization uses image-based phenotypic screening and medicinal chemistry to identify and advance selective bromodomain inhibitors of the transcriptional co-activators CBP/p300 into clinical testing (first-in-human Phase I). Development focus includes monotherapy activity and combination strategies with oncogene-targeting agents across solid tumors and hematologic malignancies.
Industries
Nr. of Employees
small (1-50)
Patents
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
US-12648947-B2
View DetailsHeterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
US-12595258-B2
View DetailsHeterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
US-12478624-B2
View DetailsCombination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer
US-12472179-B2
View Details
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
US-12648947-B2
View DetailsHeterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
US-12595258-B2
View DetailsHeterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
US-12478624-B2
View DetailsCombination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer
US-12472179-B2
View DetailsProducts
TT125-802
Orally available, selective small-molecule inhibitor targeting the bromodomain of the transcriptional co-activators CBP/p300, developed to block transcriptional networks that drive non-genetic cancer drug resistance. Evaluated in preclinical models and a multicenter Phase I clinical trial.
TT125-802
Orally available, selective small-molecule inhibitor targeting the bromodomain of the transcriptional co-activators CBP/p300, developed to block transcriptional networks that drive non-genetic cancer drug resistance. Evaluated in preclinical models and a multicenter Phase I clinical trial.
Services
Sponsorship and operational execution of first-in-human and subsequent oncology clinical trials evaluating investigational small-molecule therapeutics.
Sponsorship and operational execution of first-in-human and subsequent oncology clinical trials evaluating investigational small-molecule therapeutics.
Expertise Areas
- Transcriptional resistance mechanisms in cancer
- Medicinal chemistry for epigenetic targets
- Preclinical combination pharmacology
- Early clinical development and Phase I trial execution
Key Technologies
- Phenotypic image-based screening
- Small-molecule bromodomain inhibition
- Preclinical combination models
- RNA sequencing (RNA-seq) for pharmacodynamic readouts
News & Updates
Completion of Phase I monotherapy study in advanced solid tumors with reported clinical activity in drug-resistant NSCLC and selection of recommended dose; safety profile without thrombocytopenia reported.
Report of dose escalation in 34 patients with monotherapy activity across solid tumors; recommended Phase I dose selected based on safety and PK/PD data.
Two U.S. FDA Fast Track designations awarded to support development in EGFR-mutant and KRAS-G12C-mutant NSCLC populations with prior progression.
Initiation of Phase I clinical trial evaluating safety, tolerability, PK/PD, and pharmacodynamics of the lead CBP/p300 bromodomain inhibitor in advanced solid tumors.
Series A financing round completed to support clinical development and company growth.
Awarded an Innosuisse grant to support startup innovation projects prior to market entry and clinical translation.
Completion of Phase I monotherapy study in advanced solid tumors with reported clinical activity in drug-resistant NSCLC and selection of recommended dose; safety profile without thrombocytopenia reported.
Report of dose escalation in 34 patients with monotherapy activity across solid tumors; recommended Phase I dose selected based on safety and PK/PD data.
Two U.S. FDA Fast Track designations awarded to support development in EGFR-mutant and KRAS-G12C-mutant NSCLC populations with prior progression.
Initiation of Phase I clinical trial evaluating safety, tolerability, PK/PD, and pharmacodynamics of the lead CBP/p300 bromodomain inhibitor in advanced solid tumors.
Series A financing round completed to support clinical development and company growth.
Awarded an Innosuisse grant to support startup innovation projects prior to market entry and clinical translation.